Top Menu

Might Sinovac Become The First Chinese Issuer To Resolve An FCPA Enforcement Action?

sinovac

A long, long time ago (September 2009 to be exact) FCPA Professor highlighted how Chinese companies were increasingly seeking to raise capital in the U.S. and by registering securities in the U.S. becoming subject to a variety of U.S. laws including the Foreign Corrupt Practices Act.

There has never been an FCPA enforcement against a Chinese-based issuer, but that could change.

This post highlights the FCPA scrutiny of Beijing-based Sinovac Biotech, a company with shares traded on NASDAQ, including its recent disclosure that it is unable to file its annual report because of a bribery internal investigation.

Continue Reading

Powered by WordPress. Designed by WooThemes